Low-dose aspirin linked to 70% lower dementia risk, but there's a catch
A study from Monash University indicates that low-dose aspirin may reduce dementia risk by 70% in individuals with specific genetic markers related to platelet counts. However, the researchers noted a significant increase in major bleeding risks for the same group.
Why it matters
This research suggests a potential path for personalized medicine in dementia prevention, though it underscores the necessity of balancing efficacy with safety risks.
A new analysis from Monash University suggests that low-dose aspirin may be linked to a dramatically lower risk of dementia in older adults with certain genetic characteristics. Researchers found that people with a specific genetic profile who took aspirin had a 70 percent lower relative risk of developing dementia, raising the possibility that genetic testing could eventually help identify people who might benefit from preventive treatments.
The findings, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association , were based on genetic data from more than 13,500 participants in the landmark ASPREE Trial (Aspirin in Reducing Events in the Elderly). Scientists examined whether differences in participants' genes could help explain why aspirin might affect dementia risk differently from one person to another.
Aspirin Linked to 70% Lower Dementia Risk in Certain People
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in